Company ProfilePremium

Immutep Ltd.

Company Profile Analysis

Ticker: IMM.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Immutep Ltd. - Company showcase

Year Founded & Workforce

1987

51 Employees

Immutep Ltd. logo

Immutep Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Immutep Ltd. Overview

Immutep is a clinical-stage Australian–French biotechnology company whose entire scientific franchise is built around Lymphocyte Activation Gene-3 (LAG-3), a protein discovered by its Chief Scientific Officer, Prof. Frédéric Triebel. Its portfolio spans the full LAG-3 pharmacology spectrum: eftilagimod alfa (efti), a soluble LAG-3 fusion protein that acts as an MHC Class II agonist to activate antigen-presenting cells in oncology; IMP761, a first-in-class LAG-3 agonist antibody designed to dampen self-reactive T cells in autoimmune disease; and out-licensed antagonist assets. FY2026 was a defining reversal: the registrational TACTI-004 Phase III in first-line NSCLC was discontinued for futility in March 2026, the share price collapsed by roughly 85–90%, and a root-cause analysis subsequently pointed to manufacturing-scale differences (200L vs 2,000L product). The company now trades near its cash balance and has narrowed efti to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma, while advancing IMP761.


What the company does

Immutep discovers and develops immunotherapies that modulate the LAG-3 / MHC Class II axis. It has no marketed products, no commercial infrastructure and no product revenue. Its economic model is that of a platform-IP biotech: it funds early and mid-stage clinical development itself (often in combination with partners' approved drugs supplied free of charge, e.g., MSD's KEYTRUDA), and monetises assets through regional licences, milestone payments and royalties, while retaining rights in major markets.

Company's own description (paraphrased from FY2026 disclosures)

Immutep describes itself as a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, with a diversified portfolio that harnesses LAG-3's ability either to stimulate the immune system (oncology) or to suppress it (autoimmunity). Through early 2026 the company styled itself a "late-stage immunotherapy company"; following the TACTI-004 discontinuation its quarterly reports from April 2026 onward reverted to "clinical-stage biotechnology company" — a telling change in self-characterisation.

Independent characterisation

Immutep is best understood as a single-target (LAG-3), two-asset (efti, IMP761) company with an unusually mature clinical dataset for efti (≈600 patients across five earlier studies, per ASCO 2026 pooled analysis) that is now clouded by a failed Phase III whose most plausible explanation, per the company, is a change in drug product. The investment and strategic question has shifted from "will efti be approved in NSCLC?" to "is 200L-scale efti a different, better-performing molecule than 2,000L-scale efti — and can the company afford to prove it?"

Revenue model mix

Revenue typeDescriptionFY2026 relevance
Product sales—0%
Licensing — upfront & milestonesDr. Reddy's (efti, emerging markets), EOC Pharma (efti, Greater China), historically Novartis (ieramilimab) and GSK (GSK2831781)Dominant FY2026 driver (Dr. Reddy's upfront; US$10M of US$20M later repaid)
RoyaltiesPotential double-digit royalties from Dr. Reddy's territories; none currently earned0%
Grant incomePrimarily French research tax credit (Crédit d'Impôt Recherche) and Australian R&D incentives (classification varies)Material contributor to "other income"
Interest incomeReturn on cash and term depositsA$5.29M in FY2025 (S&P Global); declining with cash balance

Value-chain position

Immutep occupies the discovery-to-clinical-proof-of-concept segment. Manufacturing is outsourced to contract development and manufacturing organisations (the specific CMOs for 200L and 2,000L campaigns are not named in the 2026 sources reviewed); Immutep retains global manufacturing rights for efti and is obligated to supply licensees (Dr. Reddy's). Clinical trials are run via CROs and investigator-initiated trial (IIT) networks.

Customer types and end-markets

Customers today are licensing partners (pharma companies), not patients or payers. Therapeutic end-markets targeted: head and neck squamous cell carcinoma (HNSCC, specifically PD-L1 CPS<1), soft tissue sarcoma (neoadjuvant), non-small cell lung cancer (investigator-led INSIGHT-003), metastatic breast cancer (AIPAC-003 follow-up), and autoimmune diseases (IMP761 — company has cited type 1 diabetes, rheumatoid arthritis and psoriasis as potential applications, per CEO interview with Finance News Network, May 2026).

Strategy

Stated strategy (themes from FY2026 disclosures and 11 Sep 2026 release)

  1. Narrow and de-risk efti. Concentrate registration-directed development on 1L HNSCC with PD-L1 CPS<1 (supported by TACTI-003 mature OS, Fast Track designation and constructive FDA interactions) and neoadjuvant soft tissue sarcoma (EFTISARC-NEO met its primary endpoint; Orphan Drug Designation).

  2. Fix the product. Root-cause analysis identified subtle structural/analytical differences, including N-glycan structure, between 200L-scale and 2,000L-scale efti; TACTI-004 used only 2,000L product. A new 200L GMP run has been contracted for future trials. Clinical and trial-execution factors were not found to explain the outcome.

  3. Advance IMP761 in autoimmune disease under previously disclosed plans, with further Phase I data in 2H CY2026.

  4. Preserve cash. Cost-reduction measures to hold runway into 1H CY2028.

  5. Partner. Dr. Reddy's supports the revised approach; preliminary discussions with other potential partners are under way.

Strategic initiatives register (last 24 months)

DateInitiativeTypeStatus
2,025TACTI-004 global Phase III launch and US site opening after FDA Project Optimus dose workClinicalDiscontinued March 2026
2024–2026IMP761 Phase I (SAD then MAD)ClinicalOngoing
Dec 2025Dr. Reddy's licencePartnership / monetisationActive (amended economics post-repayment)
Mar–Sep 2026TACTI-004 root-cause analysisRemediationCore findings released Sept 2026; further investigation of batches ongoing
Jul 2026Cost-reduction programmeCostUnder way; quantitative targets not disclosed
Sep 2026Focused efti strategy (HNSCC CPS<1, neoadjuvant STS)PortfolioTrial starts targeted 2H CY2027, subject to designs, FDA, manufacturing, partnering and resources
Sep 2026New 200L efti manufacturing campaignCMCContracted

Guidance

ItemGuidance
Cash runwayInto 1H CY2028
Next efti trialsInitiation targeted 2H CY2027
IMP761Additional data 2H CY2026
Financial targets (revenue/margins)None (pre-revenue)
ESG commitmentsNo quantified targets disclosed

Products & Services

Immutep has no commercial products. The catalogue below covers every disclosed development asset.

Eftilagimod alfa (efti, formerly IMP321) — Oncology

AttributeDetail
ModalitySoluble LAG-3Ig fusion protein; first-in-class MHC Class II agonist
MechanismActivates antigen-presenting cells (dendritic cells, monocytes) via MHC-II, driving innate and adaptive responses incl. cytotoxic T-cell priming (company description, Sept 2026)
Development stagePhase II (registration-directed restart planned); Phase III TACTI-004 discontinued March 2026
Regulatory designationsFDA Fast Track: 1L HNSCC; FDA Fast Track: 1L NSCLC; FDA Orphan Drug: soft tissue sarcoma (April 2026)
RightsImmutep retains North America, Europe, Japan; Dr. Reddy's licensed for rest of world ex-Greater China; EOC Pharma licensed for Greater China
ManufacturingTen GMP batches previously produced at 200L scale supplied TACTI-mel, TACTI-002, INSIGHT-003; TACTI-004 used only 2,000L product; new 200L run contracted (Sept 2026)
Pricing modelNot applicable (pre-commercial)
TrialIndicationCombinationPhaseStatus (Oct 2026)Key disclosed data
TACTI-004 (KEYNOTE-F91)1L metastatic NSCLCPembrolizumab + chemotherapy vs placebo + sameIIIDiscontinued March 2026; orderly wind-downFutility analysis (N=173): ORR 42.9% efti arm vs 55.1% control; no new safety signals
TACTI-003 (KEYNOTE-C34)1L HNSCC (incl. CPS<1 cohort)PembrolizumabIIbCompleted; supports new CPS<1 strategyMature OS data cited as supporting CPS<1 focus (Sept 2026)
Planned CPS<1 HNSCC study1L HNSCC, PD-L1 CPS<1Not yet finalisedRegistration-directedTargeted start 2H CY2027Design subject to FDA discussions
EFTISARC-NEOResectable soft tissue sarcoma (neoadjuvant)Radiotherapy + pembrolizumabII (investigator-initiated)Met primary endpointBasis for STS registration-directed plan; Orphan Drug Designation
Planned STS studyNeoadjuvant STSNot yet finalisedRegistration-directedTargeted start 2H CY2027—
INSIGHT-0031L non-squamous NSCLCPembrolizumab + chemotherapyI (IIT)Mature OS reported 13 July 2026 (data cut 27 Mar 2026)Company describes as positive; contrasts with TACTI-004
TACTI-002 (KEYNOTE-798)NSCLC, HNSCCPembrolizumabIICompletedIncluded in ASCO 2026 pooled analysis
AIPAC / AIPAC-003HER2-neg / HR+ metastatic breast cancerPaclitaxelIIb / IIFollow-up ongoing (AIPAC-003)Included in pooled analysis
TACTI-melMelanomaPembrolizumabICompletedIncluded in pooled analysis
Neoadjuvant HR+/HER2- breast IITEarly breast cancerMonotherapy ± chemoII (proposed)On hold pending root cause analysis—
INSIGHT-005Solid tumours (with bintrafusp alfa, historical)—IHistorical / not active (not re-verified)—
ASCO 2026 pooled analysisFive trials (AIPAC, AIPAC-003, TACTI-mel, TACTI-002, TACTI-003)VariousAnalysisPresented May/June 2026~600 patients; reported 7.7-month median OS benefit linked to immune activation (Q4 FY26 4C summary)

IMP761 — Autoimmune disease

AttributeDetail
ModalityHumanised LAG-3 agonist IgG4 antibody; first-in-class
MechanismAgonises LAG-3 inhibitory signalling to suppress activated self-antigen-specific CD4+ and CD8+ T cells (upstream approach)
StagePhase I (placebo-controlled, double-blind, healthy participants); progressed to multiple ascending dose phase (Q3 FY26 4C)
DataFavourable safety and pharmacodynamic activity; presented EULAR 2026, London (4 June 2026); further data guided for 2H CY2026
Potential indications cited by managementType 1 diabetes, rheumatoid arthritis, psoriasis (FNN interview, May 2026)
RightsWholly owned
Third-party valuation referenceWilsons (17 July 2025, pre-TACTI-004 failure) assigned an un-risked programme valuation of A$5.9B — now dated and should be treated as historical

Out-licensed / partnered antagonist and depleting antibodies

AssetOriginal codeLicenseeMechanismStatus (Oct 2026)
IeramilimabLAG525 / IMP701NovartisAntagonist anti-LAG-3Licence terminated by Novartis effective 9 Aug 2026 for clinical inactivity; rights revert (terms of reversion not disclosed)
GSK2831781IMP731GSKDepleting anti-LAG-3Development discontinued by GSK (c.2019); current contractual status not re-verified

Diagnostics / research reagents

Third-party profiles list a collaboration with Laboratory Corporation of America (LabCorp); the scope (believed to relate to LAG-3 research/diagnostic reagents) is not described in 2026 filings reviewed — not publicly disclosed in detail.

Financial Narrative

Accounting basis: Australian Accounting Standards / IFRS; Nasdaq filings on Form 20-F. FY2022–FY2025 figures below are S&P Global Market Intelligence standardized data (via StockAnalysis.com). FY2026 figures are company-reported from the FY2026 results (late August 2026, via Quartr summary) and Q4 FY26 Appendix 4C. Blank cells = not publicly disclosed / not yet available in verified sources.

Income statement

Note: Quartr's FY2026 summary gives FY2025 R&D and IP expense as A$61.4M, consistent with S&P. EBITDA is not meaningful for a pre-revenue biotech and is not reported by the company; approximating it as operating income plus small D&A (intangible amortisation ~A$1–1.3M p.a., derived from intangible balance decline) gives an EBITDA loss marginally smaller than operating loss. Margins (gross, operating, net) are not meaningful because revenue is non-recurring licensing/grant income; for reference, FY2025 net loss was ~12x S&P operating revenue.

Revenue CAGR: Operating revenue FY2022→FY2025 (S&P): from 4.71 to 5.03, CAGR ≈ +2.2% p.a. Company-reported total revenue and other income FY2025→FY2026: +135%, driven by Dr. Reddy's licensing revenue and higher grant income — non-recurring in nature.

Commentary. The P&L tells the story of a company scaling into a Phase III. R&D expense nearly tripled from A$31.3M (FY2022) to A$91.9M (FY2026), with the FY2026 figure inflated by TACTI-004 activity and its close-out costs. Corporate overhead has been tightly controlled at A$7–10M, so R&D intensity (R&D as share of total opex) rose from ~81% to ~91%. The net loss widened every year — from A$32.2M in FY2022 to A$79.3M in FY2026 — and FY2026 would have been worse without the Dr. Reddy's licence income. The A$3.1M impairment of efti-related IP is small relative to the economic damage because Immutep carries little capitalised IP (intangibles A$7.1M at June 2025). The inflection point is FY2027: management's cost-reduction programme and the end of Phase III spending should cut gross burn sharply, which underpins the runway guidance into 1H CY2028.

Balance sheet

Interim reference (31 Dec 2025, S&P Global): cash and short-term investments A$99.13M; receivables A$37.52M (incl. Dr. Reddy's upfront receivable ~A$29.9M); total current liabilities A$47.01M (elevated, consistent with recognition of contract-related obligations); equity A$98.9M; shares 1,474M. Cash at 31 March 2026: ~A$110.6M (Q3 FY26 4C), stated as better than FY2026 budget, before TACTI-004 wind-down and the US$10M Dr. Reddy's repayment. Cash at 30 June 2026: A$68.87M (Q4 FY26 4C). Long-term debt is a small French government-supported loan plus leases.

Commentary. Immutep has always been effectively debt-free; its balance sheet is cash plus a small amount of capitalised IP. Equity has been replenished by repeated placements (common stock grew A$177M between FY2022 and FY2025, including the ~A$100M February 2024 raise). The FY2026 decline in cash from A$129.7M to A$68.9M (-47%) reflects peak Phase III spending, wind-down costs and the US$10M repayment, partially offset by the Dr. Reddy's upfront. Book equity at 30 June 2026 is not yet verified but will be materially lower than A$98.9M (Dec 2025) given the H2 loss.

Cash flow

"Derived" rows are analyst calculations from balance-sheet movements and are approximations. FY2026 net change uses A$129.69M → A$68.9M.

Commentary. Underlying burn rose from ~A$35M p.a. (FY2022–FY2024) to ~A$55M in FY2025 and an estimated A$85–90M gross in FY2026 before licensing receipts (derived: A$60.8M decline in cash plus ~A$15M net Dr. Free cash flow is structurally negative and equivalent to operating cash flow because capex is negligible.

Ratios

Derived from S&P Global standardized data. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a pre-revenue, net-cash biotech (EBITDA negative; interest expense ~A$0.04M p.a.; no inventory or trade receivables cycle). FY2026 net cash/market cap uses A$68.9M cash vs ~A$75M market cap (Aug 2026 price) — derived.

Commentary on trends and drivers. Return metrics deteriorated in FY2025 as R&D accelerated and will be worst in FY2026. Liquidity ratios remain very strong because liabilities are small, but the 31 December 2025 current ratio (~3.0x) showed a temporary rise in obligations tied to the Dr. Reddy's agreement. The single most important ratio for Immutep is months of runway: management guides into 1H CY2028 (≈18–21 months from 30 June 2026), which requires average quarterly net burn of roughly A$9–11M — less than half the FY2026 run-rate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

Segment metricFY2022FY2023FY2024FY2025FY2026

Single segment operating revenue (AUD Mn, S&P standardized)

4.713.513.845.03—

Single segment total revenue and other income (AUD Mn, company-reported)

———10.324.2

Single segment net loss (AUD Mn)

-32.21-39.90-42.72-61.43-79.3

Contribution to group revenue (%)

100100100100100

Group Entities

EntityJurisdictionFunction

Immutep Limited

Australia

Listed parent; corporate, finance, investor relations (Sydney)

Immutep S.A.S.

France

LAG-3 IP owner; research, CMC and translational science; counterparty to Dr. Reddy's licence; patents co-owned per Q3 FY26 4C

Immutep GmbH

Germany

—

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Operating revenue (AUD Mn, S&P standardized)

4.713.513.845.03—

Total revenue and other income (AUD Mn, company-reported)

———10.324.2

R&D and IP expense (AUD Mn)

31.3436.2641.5561.4191.9

Corporate administrative expense (AUD Mn)

7.218.688.858.649.6

Gross profit (AUD Mn, S&P standardized; R&D treated as cost of revenue)

-26.63-32.75-37.70-56.37—

Operating income (AUD Mn)

-33.84-41.43-46.56-65.01—

Interest and investment income (AUD Mn)

0.220.943.885.29—

FX gain/loss (AUD Mn)

1.230.620.11-1.53—

Impairment of efti-related IP (AUD Mn)

00003.1

Pre-tax loss excl. unusual items (AUD Mn)

-31.89-39.76-42.59-61.29—

Net loss after tax (AUD Mn)

-32.21-39.90-42.72-61.43-79.3

Basic and diluted loss per share (A$ cents)

————5.39

Dividends per share (AUD)

00000

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

80.00123.42161.7967.41—

Short-term investments / term deposits (AUD Mn)

0020.0962.28—

Cash, equivalents and term deposits (AUD Mn)

80.00123.42181.88129.6968.9

Total assets (AUD Mn)

102.17147.45201.58156.98—

Total debt incl. leases (AUD Mn)

1.731.231.591.63—

Short-term debt and leases (AUD Mn)

0.170.190.231.31—

Long-term debt and leases (AUD Mn)

1.561.051.360.31—

Net cash (AUD Mn)

78.26122.19180.28128.07—

Shareholders' equity (AUD Mn)

94.08136.47189.52143.64—

Goodwill (AUD Mn)

0.110.110.110.11—

Other intangibles (AUD Mn)

10.449.388.137.09—

Working capital (AUD Mn)

84.40125.19180.86136.34—

Shares outstanding (M)

866.241,1871,4531,460—

Contributed equity / common stock (AUD Mn)

357.75436.61532.44535.07—

Accumulated losses (AUD Mn)

-302.34-339.93-382.65-444.08—

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Net change in cash, equivalents and term deposits (AUD Mn)

19.4143.4258.46-52.19-60.79

Increase in contributed equity — proxy for equity raised (AUD Mn)

53.9978.8695.832.63—

Derived underlying cash burn (AUD Mn, change in cash less equity raised; includes FX and interest)

-34.58-35.44-37.37-54.82—

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%, net loss / average equity)

-38.5-34.6-26.2-36.9—

ROA (%, net loss / average total assets)

-35.0-32.0-24.5-34.3—

Current ratio (x)

14.213.818.211.7—

Debt to equity (x)

0.0180.0090.0080.011—

Net cash to market cap at year end (x)

————0.92

Geographic Revenue

Region / sourceFY2024FY2025

Licence income from Dr. Reddy's — India-headquartered licensee, territory ex-NA/EU/JP/China (AUD Mn)

00

Valuation Snapshot

MetricValueSource / date

ASX: IMM last verified price

A$0.051

StockAnalysis, 19 Aug 2026

ASX: IMM price at Q4 4C release

A$0.047 (closed A$0.052)

InvestSMART, 30 Jul 2026

Nasdaq: IMMP ADS price

US$0.3924

Yahoo Finance, 23 Jul 2026

IMMP 52-week range

US$0.29 – US$3.53

Yahoo Finance, Jul 2026

IMMP market cap (intraday)

US$57.8M

Yahoo Finance, Jul 2026

IMMP beta (5Y monthly)

2.22

Yahoo Finance

IMMP 1-year analyst target (mean)

US$1.50

Yahoo Finance, Jul 2026 (likely stale)

Performance (IMMP ADS, approximate)

1-year

3-year

Valuation Multiples

MultipleImmutepComment

P/B

~1.0x or below (derived; FY2026 equity not yet verified)

Trades near net cash

Capital Markets

ItemDetail

Dividend history and policy

Never paid; none expected

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

Not applicable (debt ~A$1.6M incl. leases at June 2025)

Metric

FY2022

Shares outstanding at year end (M)

866.24

Dividends per share (AUD)

0

Analyst Conclusions

Guidance and consensus

Management guides cash runway into 1H CY2028, further IMP761 Phase I data in 2H CY2026, and initiation of registration-directed efti trials in CPS<1 HNSCC and neoadjuvant STS in 2H CY2027, contingent on trial designs, regulatory discussions, manufacturing, partnering and resources. No revenue or earnings guidance is provided.

Bull case

  1. The manufacturing explanation holds. If 200L product restores the immune-activation profile seen in ~600 earlier patients, efti's prior efficacy signals (pooled 7.7-month OS benefit; INSIGHT-003) re-emerge, and the market is pricing the asset near zero (EV ≈ A$6M).

  2. Orphan and Fast Track paths are capital-efficient. STS (Orphan) and CPS<1 HNSCC (Fast Track) can be pursued with smaller trials than a 1L NSCLC Phase III.

  3. IMP761 optionality. A positive MAD readout in 2H CY2026 could attract an I&I partner — the asset is first-in-class and wholly owned.

Bear case

  1. TACTI-004 may simply be the truth. Earlier datasets were mainly single-arm or small; the randomised, double-blind Phase III showed a worse ORR (42.9% vs 55.1%) — glycan differences may be a convenient rather than causal explanation.

  2. Cash is insufficient for registration. A$68.9M cannot fund two registrational programmes plus IMP761; dilution at ~A$0.05 is likely severe.

  3. Commercial-scale problem. Even if 200L works, commercialising efti requires a scalable process demonstrating equivalence — potentially years of CMC work.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
Late Oct 2026Q1 FY27 Appendix 4C — burn rate versus runway guidance
Nov 2026AGM — remuneration report vote, board renewal
2H CY2026IMP761 additional Phase I (MAD) data
2H CY2026 – 1H CY2027Completion of root-cause analysis; batch-comparison data
1H CY2027200L manufacturing run completion and release
1H CY2027FDA feedback on CPS<1 HNSCC and STS trial designs
OngoingPartnering announcements; class action developments; Nasdaq compliance status

Analyst verdict

Immutep enters FY2027 as a fundamentally different company from the one investors owned a year ago. Twelve months ago it was a "late-stage" LAG-3 leader with a registrational Phase III enrolling quickly, a fresh emerging-markets licence with Dr. Reddy's, and a market value several hundred million dollars above its cash. Today it is a cash-shell-plus-options story: market capitalisation of roughly A$75M versus A$68.9M of cash, implying the market ascribes almost no value to efti, IMP761, the Dr. Reddy's milestone stack or two decades of LAG-3 know-how.

That pricing is harsh but not irrational. The TACTI-004 result was not a near miss — the efti arm underperformed placebo on response rate — and the proposed explanation, a glycosylation difference between 200L and 2,000L drug product, remains a hypothesis that will not be tested clinically until 2H CY2027 at the earliest. Even if correct, it raises uncomfortable questions about process control and commercial scalability. Meanwhile, the company must fund that test from a balance sheet that shrank by nearly half in FY2026 and could face material dilution.

The asymmetric case rests on three things the market is currently discounting: a credible scientific rationale for the product-scale hypothesis (a markedly different immune-activation profile in TACTI-004 versus ~600 earlier patients), capital-efficient regulatory routes (Orphan STS, Fast Track CPS<1 HNSCC), and a wholly owned, first-in-class autoimmune asset with near-term data. A positive IMP761 readout or a partnering deal could quickly re-rate a stock trading near cash.

Our assessment: high-risk, speculative, event-driven. Downside from current levels is cushioned by cash but exposed to burn and dilution; upside is binary on IMP761 data and validation of the manufacturing thesis. Investors should watch quarterly burn, root-cause disclosures and partnering news before assigning value beyond cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundEducation

Marc Voigt

Chief Executive Officer and Executive Director

CEO since 2014; previously CFO/CBO at Prima BioMed; earlier investment banking and biotech roles in Germany

—

Prof. Frédéric Triebel, MD PhD

Chief Scientific Officer / Chief Medical Officer

Discoverer of LAG-3; founder of Immutep S.A.; prior academic career at Institut Gustave Roussy

MD, PhD (France)

Deanne Miller

Chief Operating Officer, General Counsel and Company Secretary

—

Law

Board of Directors

NameRoleIndependence

Dr Russell Howard

Non-Executive Chairman

Independent

Pete Meyers

—

Independent

Marc Voigt

Executive Director and CEO

Not independent

Major Shareholders

Holder categoryDetail

Top 10 institutional holders

Not publicly disclosed in sources reviewed (see Annual Report top-20 holder list; ADS depositary will appear as a top holder)

Competitive Landscape

Key Competitors

CompetitorAsset(s)MechanismAreaRelative positioning vs Immutep

Bristol Myers Squibb

Opdualag (nivolumab + relatlimab)

LAG-3 antagonist

Melanoma (approved), other tumours

Only approved LAG-3 product; validates target but via antagonism

Regeneron

Fianlimab (+ cemiplimab)

LAG-3 antagonist

Melanoma, NSCLC

Late-stage, far better funded

Merck & Co. (MSD)

Favezelimab (development discontinued in several settings); KEYTRUDA

LAG-3 antagonist / PD-1

Multiple

Partner and benchmark; KEYTRUDA is standard of care

Roche

Tiragolumab (TIGIT), atezolizumab

IO combinations

NSCLC, HNSCC

Example of failed IO add-on Phase III programmes

MacroGenics

Tebotelimab (PD-1 x LAG-3 bispecific)

Bispecific

Solid tumours

Small-cap peer; deprioritised

Incyte

INCAGN2385 (LAG-3)

Antagonist

Solid tumours

Early stage

Merus / Bicara / Johnson & Johnson-type HNSCC players

Petosemtamab (Merus), ficerafusp alfa (Bicara), amivantamab

EGFR-based

1L/2L HNSCC

Key competitive threat for CPS<1 HNSCC

Gilead / Arcus

Domvanalimab, zimberelimab

TIGIT / PD-1

NSCLC

IO combination competitor

AnaptysBio

Rosnilimab

PD-1 agonist

Rheumatoid arthritis, UC

Direct conceptual competitor to IMP761 (checkpoint agonism for autoimmunity)

Eli Lilly

Peresolimab

PD-1 agonist

Rheumatoid arthritis

—

Amgen / Kyowa Kirin

Rocatinlimab

OX40

Atopic dermatitis

T-cell modulation in I&I

Peer Comparison FY2026

MetricImmutep (FY2026)BMS (FY2024)Regeneron (FY2024)MacroGenics (FY2024)

Revenue (local currency)

A$24.2M total revenue and other income

~US$48.3B

~US$14.2B

—

Revenue growth

+135% (non-recurring)

~+7%

~+8%

—

Operating margin

Not meaningful (loss-making)

Negative in 2024 due to IPRD charges

~30%

Negative

R&D intensity (% of revenue)

300%

~20% (ex-IPRD)

~35%

100%

Recent Developments

--

Company Snapshot

$3.2M

Revenue

51

Employees

1987

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Net cash and no debt: A$68.9M cash, equivalents and term deposits at 30 June 2026; total debt only A$1.63M at June 2025.
  • Runway guidance: Into 1H CY2028 after cost reductions (Q4 FY26 4C).
  • Large efti dataset: ~600 patients across five earlier trials, pooled analysis presented at ASCO 2026 with a 7.7-month median OS benefit reported.
  • Regulatory designations: FDA Fast Track in 1L HNSCC and Orphan Drug Designation in STS (April 2026).
  • Positive IIT data: EFTISARC-NEO met its primary endpoint; INSIGHT-003 mature OS described as positive (13 July 2026).
  • Partner support: Dr. Reddy's backs revised approach and contributed technical expertise to root-cause analysis.
  • Wholly owned, first-in-class IMP761 with favourable Phase I safety (EULAR 2026).

Weaknesses

  • Phase III failure: TACTI-004 ORR 42.9% (efti) vs 55.1% (placebo) at futility analysis (N=173).
  • Manufacturing uncertainty: N-glycan differences between 200L and 2,000L product; commercial-scale supply unresolved.
  • Escalating losses: net loss up from A$32.2M (FY2022) to A$79.3M (FY2026).
  • Revenue quality: FY2026 income largely one-off; US$10M of the Dr. Reddy's upfront repaid.
  • Asset attrition: Novartis terminated ieramilimab licence (effective 9 Aug 2026); GSK asset discontinued.
  • Long gap to next efti data: next trials not before 2H CY2027.

Opportunities

  • CPS<1 HNSCC: an underserved population where PD-1 monotherapy is weak; Fast Track supports accelerated paths.
  • Orphan STS: smaller, cheaper registrational path with seven-year US orphan exclusivity potential.
  • Partnering: management in preliminary discussions with additional potential partners (Sept 2026).
  • IMP761 data in 2H CY2026 could re-rate the company toward an I&I story.
  • Dr. Reddy's milestones: up to US$349.5M remain contractually available if development succeeds.
  • Valuation floor: market cap approximately equal to cash creates M&A/strategic optionality.

Threats

  • Hypothesis risk: 200L product may not restore efficacy; the root-cause analysis remains incomplete.
  • Dilution: at ~A$0.05/share, any raise to fund registrational trials would be highly dilutive.
  • Competition in HNSCC from EGFR-bispecifics (e.g., petosemtamab, ficerafusp alfa).
  • Litigation: putative US securities class action filed after 13 March 2026.
  • Nasdaq listing compliance: IMMP ADS traded ~US$0.39 (July 2026), below the US$1 minimum bid requirement (no deficiency notice verified).
  • Talent retention amid cost cuts and share-based compensation underwater.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1H CY2025TACTI-004 enrolment underway internationallyPhase III execution
Jul 2025Wilsons issues IMP761 research (Overweight, risked PT A$1.20)Peak sell-side optimism
Aug 2025FY2025 results: net loss A$61.4M; cash and term deposits ~A$129.7MPre-crisis baseline
Oct 2025INSIGHT-003 data presented (poster)Supportive NSCLC dataset
Q2 FY26FDA Project Optimus dose work completed; TACTI-004 opens US sitesUS registrational readiness
8 Dec 2025Dr. Reddy's licence: US$20M upfront, up to US$349.5M milestonesLargest deal ever
Dec 2025Cash and term deposits ~A$99.1M at 31 Dec 2025In line with budget
Jan 2026~A$30M upfront received; Q2 FY26 4C (29 Jan)Liquidity
6 Feb 2026TACTI-004 reaches 50% enrolment (378 patients)Momentum
Feb 2026H1 FY2026 resultsPre-futility
13 Mar 2026IDMC recommends TACTI-004 discontinuation after interim futility analysisValue-destroying event; runway extended beyond prior Q2 CY2027 guidance
Mar 2026IMP761 Phase I update; progresses to MADPipeline continuity
Mar–Apr 2026Putative US securities class action filed (not served)Litigation risk
Apr 2026FDA Orphan Drug Designation for efti in STSRegulatory asset
30 Apr 2026Q3 FY26 4C: cash ~A$110.6M at 31 March; root-cause analysis across clinical, operational, analytical and manufacturing aspects; neoadjuvant breast IIT on holdTransparency on obligations
May 2026CEO interview: root-cause analysis guided for Q3; IMP761 at EULARCommunication
May/Jun 2026ASCO 2026: pooled analysis of five efti trials (~600 patients)Mechanistic support
4 Jun 2026IMP761 Phase I data at EULAR 2026, LondonAutoimmune validation (early)
By Jun 2026US$10M repaid to Dr. Reddy'sNet upfront halved
13 Jul 2026INSIGHT-003 mature OS; TACTI-004 immune monitoring shows different profile; ORR 42.9% vs 55.1%Divergence points to product issue
30 Jul 2026Q4 FY26 4C: cash A$68.87M; cost reductions; seven patents grantedRunway into 1H CY2028
9 Aug 2026Novartis ieramilimab licence termination effectiveLoss of milestone optionality
Late Aug 2026FY2026 results: net loss A$79.3M; R&D A$91.9M; A$3.1M impairmentFinancial reset
11 Sep 2026Focused efti strategy; 200L vs 2,000L N-glycan difference; new 200L run; trials targeted 2H CY2027Strategic reset
2H CY2026 (pending)Further IMP761 Phase I dataNext catalyst
Oct–Nov 2026 (expected)Q1 FY27 4C (late Oct) and AGM (typically Nov)Governance test

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Total revenue and other income rose from AUD 10.3 Mn in FY2025 to AUD 24.2 Mn in FY2026.
Immutep Ltd. — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income———10.324.2
Operating revenue4.73.53.85—
Gross profit (A$ M, S&P standardized; R&D treated as cost of revenue)-26.6-32.8-37.7-56.4—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Immutep, "Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91)", ASX, 6 Feb 2026 (announcements.asx.com.au)
  2. Immutep, "TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis", 13 Mar 2026 (via 1stOncology and OncLive) (onclive.com)
  3. Immutep, Quarterly Activities Report & Appendix 4C Q3 FY26, 30 Apr 2026 (announcements.asx.com.au)
  4. Immutep, Clinical update: INSIGHT-003 mature OS and TACTI-004 update, 13 Jul 2026 (immutep.com)
  5. InvestSMART summary of Q4 FY26 Appendix 4C, 30 Jul 2026 (investsmart.com.au)
  6. Quartr, Immutep H2 FY2026 results summary, 30 Aug 2026 (quartr.com)
  7. Pharmacally, "Immutep Refocuses Efti Development on HNSCC and STS", 11 Sep 2026 (citing Immutep release of same date) (pharmacally.com)
  8. SmallCaps, "Immutep Refocuses Efti Development Following TACTI-004 Study Review", Sep 2026 (smallcaps.com.au)
  9. Panabee, Immutep strategy pivot and Novartis licence termination (panabee.com)
  10. BioSpectrum Asia, Immutep–Dr. Reddy's licence, 8 Dec 2025 (biospectrumasia.com)
  11. Dr. Reddy's NSE disclosure, 8 Dec 2025 (nsearchives.nseindia.com)
  12. Biotech Dispatch, INSIGHT-003 and TACTI-004 coverage, Jul 2026 (biotechdispatch.com.au)
  13. Finance News Network, CEO interview, May 2026 (finnewsnetwork.com.au)
  14. StockAnalysis.com (S&P Global Market Intelligence data), Immutep income statement and balance sheet (stockanalysis.com)
  15. Yahoo Finance, IMMP quote and profile, Jul 2026 (finance.yahoo.com)
  16. Morningstar Australia, Immutep profile (morningstar.com.au)
  17. Wilsons, "IMP761: Can I&I success fund I-O upside?", 17 Jul 2025 (immutep.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.